Therefore, the introduction of SGLT2 inhibitors should be considered as early as possible in the treatment of some of the most common chronic diseases in the elderly—chronic kidney diseases, T2D, and CV diseases. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.